CRISPR Therapeutics has $1.3B quick assets to fund pipeline development

• CRISPR Therapeutics (NASDAQ:CRSP) reported Q3 results this morning. Fundamentals continue to reflect its clinical-stage status. Funding should not be a near-term concern considering its $1.3B balance of cash (~$1B) and marketable securities (~$300M).
• Development update:
• Additional data from two Phase 1/2 studies of CTX001 in beta thalassemia and sickle cell disease (SCD) should be available this quarter.
• CTX001 has PRIME status in Europe for severe SCD and Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA and Orphan Drug Designation from the European Commission for both transfusion-dependent beta-thalassemia and SCD.
• Additional data from a Phase 1 study of CTX110 in CD19+ B-cell blood cancers should be available in 2021.
• Topline results from a Phase 1 trial of CTX120 in multiple myeloma expected in 2021.
• Phase 1 trial evaluating an allogeneic stem cell-derived therapy for type 1 diabetes should launch in 2021 (with ViaCyte).
• https://seekingalpha.com/news/3627237-crispr-therapeutics-sitting-on-1_3b-in-quick-assets-to-fund-pipeline-development